Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

2012 ◽  
Vol 31 (2) ◽  
pp. 103-109 ◽  
Author(s):  
Roberto Latagliata ◽  
Massimo Breccia ◽  
Carmen Fava ◽  
Fabio Stagno ◽  
Mario Tiribelli ◽  
...  
Keyword(s):  
Risk Factors ◽  
Elderly Patients ◽  
Chronic Myelogenous Leukaemia ◽  
Myelogenous Leukaemia ◽  
Pleural Effusions ◽  
Incidence Risk ◽  
Dasatinib Treatment

scholarly journals Acute kidney injury in elderly patients: narrative review on incidence, risk factors, and mortality

2018 ◽  
Vol Volume 11 ◽  
pp. 217-224 ◽  
Author(s):  
Lais Gabriela Yokota ◽  
Beatriz Sampaio ◽  
Erica Pires Rocha ◽  
André Balbi ◽  
Iara Sousa Prado ◽  
...  
Keyword(s):  
Risk Factors ◽  
Acute Kidney Injury ◽  
Elderly Patients ◽  
Kidney Injury ◽  
Narrative Review ◽  
Incidence Risk

scholarly journals Incidence, risk factors and outcomes of postoperative acute kidney injury in elderly patients undergoing abdominal surgery

2019 ◽  
Author(s):  
Jianghua Shen ◽  
Simiao Zhao ◽  
Denglei Ma ◽  
Minghui Chen ◽  
Suying Yan
Keyword(s):  
Risk Factors ◽  
Acute Kidney Injury ◽  
Abdominal Surgery ◽  
Elderly Patients ◽  
Kidney Injury ◽  
Intraoperative Management ◽  
Combined Administration ◽  
Incidence Risk ◽  
Independent Risk Factors ◽  
Postoperative Aki

Abstract Objectives To investigate the incidence, risk factors and outcomes of acute kidney injury (AKI) in elderly patients undergoing abdominal surgery. Methods A retrospective study exploring the incidence of AKI in patients older than 75 years within 48 hours after abdominal surgery was conducted. Patients' preoperative characteristics, intraoperative management including medication and outcomes were evaluated for associations with AKI using a logistic regression model.Results During the 2.5-year period, a total of 409 abdominal surgeries were performed. Both pre- and post-operative SCr measurements were available for 329 (80.4%) cases. 26 patients (7.9%) developed AKI, of whom 25 (7.6%) and 1 (0.3%) reached the AKI stages 1 and 2 respectively. Older age (83.0 vs 80.4 years; p=0.002), preoperative liver function damage represented by AST (47.5 vs 21.0 IU/L; p=0.023), intraoperative combined administration of hydroxyethyl starch(HES) and furosemide (15.38% vs 1.65%; p=0.003) were independent risk factors for the development of postoperative AKI. Furthermore, AKI patients had significantly longer ICU stay (3 vs 0 days; p<0.001) and higher in-hospital mortality (23.08% vs 2.31%; p<0.001)Conclusion Intraoperative combined administration of HES and furosemide is an independent factor which can be controlled by anesthesiologists and surgeons for AKI. This provides important recommendations for reducing the incidence of postoperative AKI.

An Economic Evaluation of Dasatinib for the Treatment of Imatinib-Resistant Patients with Chronic Myelogenous Leukaemia.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4535-4535
Author(s):  
Matthew J Taylor ◽  
Ruth C Saxby ◽  
Catherine Davis
Keyword(s):  
Resource Use ◽  
Research Funding ◽  
Chronic Myelogenous Leukaemia ◽  
Chronic Phase ◽  
Cost Effective ◽  
Myelogenous Leukaemia ◽  
Current Health ◽  
Imatinib Resistant ◽  
Lifetime Costs ◽  
Dasatinib Treatment

Abstract Abstract 4535 BACKGROUND & AIMS Chronic myelogenous leukaemia (CML) is a progressive disease that is associated with significant health and economic burden. Whilst the short-term response to current treatments such as imatinib is relatively high, durable response is difficult to achieve in patients with resistant disease. This study estimates the lifetime costs and health outcomes associated with the use of dasatinib in the treatment of imatinib-resistant CML patients. METHODS A Markov model was developed to estimate the lifetime costs and health outcomes associated with current treatments for CML in the chronic phase of the disease who are resistant to imatinib 400 mg daily. Three treatment options were modelled: (i) dasatinib 100mg, (ii) imatinib 800mg and (ii) nilotinib 800mg. Patients progressed through the stages of the disease at different rates, based on their initial best response to treatment (drawn from existing clinical trials). Unit costs were drawn from national databases, and were multiplied by resource use to estimate total costs. Resource use was dependent upon the patient's current health state and response level. Health benefits were measured using quality-adjusted life years (QALYs). Quality of life was based on the patient's current health status and level of response; utility values were obtained through a survey. Results were discounted at 3.5% p.a and probabilistic sensitivity analysis was undertaken to estimate the level of confidence around the results of the models. RESULTS This analysis shows that for imatinib-resistant patients starting treatment in the chronic phase, dasatinib treatment is both more effective and less costly than treatment with high-dose imatinib; it is the dominant treatment in terms of cost-effectiveness. Specifically, over a patient's lifetime, dasatinib treatment is associated with an average of 5.70 (discounted) QALYs, compared to 5.56 with imatinib. During that same period, dasatinib treatment would be expected to cost £260,866, compared with £311,685 for imatinib. The avoided costs result from reduced hospital admissions and other healthcare resource in patients treated with dasatinib. When compared against nilotinib, dasatinib produced an additional 0.30 QALYs, and incurred a total increase in costs of £2,546. The incremental cost-effectiveness ratio was, therefore, £8,554 per QALY. CONCLUSIONS This analysis has demonstrated that dasatinib is more effective than both imatinib and nilotinib in the treatment of imatinib-resistant patients with chronic-phase CML. The analysis estimates dasatinib treatment to be less costly than imatinib in the long term; therefore, dasatinib is a cost-effective option in the treatment of CML. Whilst dasatinib treatment results in slightly increased costs than nilotinib, due to predicted increased life expectancy, it remains a cost-effective treatment. Disclosures: Taylor: York Health Economics Consortium: Consultancy, Research Funding. Saxby:York Health Economics Consortium: Consultancy, Research Funding. Davis:Bristol-Myers Squibb: Employment.

Incidence, Risk Factors, and Complications of Postoperative Delirium in Elderly Patients Undergoing Radical Cystectomy

Urology ◽  
2013 ◽  
Vol 81 (1) ◽  
pp. 123-129 ◽  
Author(s):  
Michael C. Large ◽  
Chad Reichard ◽  
Joshua T.B. Williams ◽  
Charles Chang ◽  
Sandip Prasad ◽  
...  
Keyword(s):  
Risk Factors ◽  
Elderly Patients ◽  
Radical Cystectomy ◽  
Postoperative Delirium ◽  
Incidence Risk
Sign in / Sign up

Export Citation Format

Share Document